"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
Front Oncol
.
2014 Nov 18:4:334.
doi: 10.3389/fonc.2014.00334.
eCollection 2014.
Authors
Elda Tagliabue
1
,
Manuela Campiglio
1
Affiliation
1
Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
PMID:
25478327
PMCID:
PMC4235291
DOI:
10.3389/fonc.2014.00334
No abstract available
Keywords:
HER2; breast cancer; omics; targeted therapy; trastuzumab resistance.